Recognizing Adverse Reactions

How Reactions Are Classified

Trials grade intensity from mild to severe; the FDA's "serious" means an outcome like hospitalization or a life-threatening event. Labels give rates against placebo, while FDA reviews of research compounds and user reports name problems without rates or proof of cause. Our overview of peptide warning signs covers each class.

Common Adverse Reactions

GH Secretagogues

Reaction	Symptoms	Severity	Source
Water retention	Swelling, puffiness	Mild	MK-677 trial; users
Increased hunger	Appetite, often fading	Mild	MK-677 trial
Joint or muscle discomfort	Stiffness, pain	Mild-Moderate	Trial (muscle); users (joints)
Carpal tunnel symptoms	Tingling, numbness	Moderate	User reports
Blood sugar changes	Often none; higher fasting glucose	Moderate	MK-677 trial

Edema and muscle pain were mild and transient in a 2-year MK-677 trial; a hip-fracture trial stopped early over a heart failure signal.

IGF-1 Peptides

Reaction	Symptoms	Severity	Source
Hypoglycemia	Sweating, dizziness, hunger	Moderate-Severe	Mecasermin label; users
Headache	Variable	Mild	Vendor lists
Joint pain or bloating	Aching, water retention	Mild	Vendor lists

IGF-1 LR3 has no human data. The label for mecasermin, a prescription IGF-1, reports hypoglycemic seizures.

Healing Peptides

Reaction	Symptoms	Severity	Source
Injection site reaction	Redness, swelling, pain	Mild	User and vendor reports
Fatigue or low mood	Tiredness, anxiety	Mild	User reports
Nausea or dizziness	Variable	Mild	Vendor lists

A 2025 systematic review found no clinical safety data for BPC-157 in humans.

Injection-Site Reactions and Infection

Redness or pain at the site affected 25% of people on tesamorelin (Egrifta SV) versus 14% on placebo, per its label. Infection looks different: MedlinePlus describes cellulitis as spreading redness that may bring fever and chills. Health Canada's April 2026 advisory says unauthorized injectable peptides can cause infections and may contain bacteria or endotoxins.

Serious Warning Signs

Immediate Medical Attention

Symptom	Possible Cause	Urgency
Severe hypoglycemia	IGF-1 excess	Emergency
Chest pain	Cardiac concern	Emergency
Trouble breathing, facial swelling	Anaphylaxis	Emergency
Severe abdominal pain	Possible pancreatitis (GLP-1 labels)	Emergency
Severe headache	Multiple causes	Urgent
Vision changes	Various	Urgent

Hives or rash affected 4% of tesamorelin trial patients. MedlinePlus says anaphylaxis, the severe form, often develops within minutes. Trouble breathing or facial swelling are typical signs. The mecasermin and Wegovy labels both report it.

Signs of Overdose

Sign	Significance	Source
Severe fluid retention	Excessive GH effect	User reports
Marked joint pain	Excessive growth effects	User reports
Hypoglycemia events	IGF-1 excess	Label; users

What Users Commonly Track

Community symptom logs often cover energy levels and sleep quality. Many note appetite and mood too; none are validated.

How Responses Differ by Severity

The tesamorelin and mecasermin labels, like Wegovy's, say the drug is stopped and prompt medical attention sought if hypersensitivity is suspected. Egrifta SV's patient information calls for emergency help right away for a serious allergic reaction, and the mecasermin patient information does too for severe hypoglycemia when the person can't respond. Stopping is covered in discontinuation criteria; reactions can be reported to the FDA through MedWatch.

What We Still Don't Know

Research-use peptides lack systematic safety data, and contamination makes it hard to tell whether a reaction comes from the peptide or the vial.